诺和诺德继续出手买买买。10月15日,诺和诺德宣布,引进Omeros的MASP-3抗体OMS906,用于治疗罕见血液疾病和肾脏疾病。根据协议,诺和诺德支付3.4亿美元预付款和近期里程碑,若计入潜在研发和商业里程碑总金额最高达21亿美元,另加基于净销售额的分级分成。加科思贯彻聚焦战略。日前,加科思宣布,与海松资本及一名产业合作方签署增资及股权转让协议。根据本次协议,海松资本将以人民币1.25亿元...
Source Link诺和诺德继续出手买买买。10月15日,诺和诺德宣布,引进Omeros的MASP-3抗体OMS906,用于治疗罕见血液疾病和肾脏疾病。根据协议,诺和诺德支付3.4亿美元预付款和近期里程碑,若计入潜在研发和商业里程碑总金额最高达21亿美元,另加基于净销售额的分级分成。加科思贯彻聚焦战略。日前,加科思宣布,与海松资本及一名产业合作方签署增资及股权转让协议。根据本次协议,海松资本将以人民币1.25亿元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.